Months later, LogicBio exits FDA clinical hold for gene editing drug but won't restart trial until next quarter

Tyler Patchen

News Reporter

LogicBio Therapeutics has received some good news this morning as the FDA has lifted a three-month clinical hold on one of the company’s primary trials …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Months later, LogicBio exits FDA clinical hold for gene editing drug but won't restart trial until next quarter

Tyler Patchen

News Reporter

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Months lat­er, Log­icBio ex­its FDA clin­i­cal hold for gene edit­ing drug but won't restart tri­al un­til next quar­ter

Tyler Patchen

News Reporter

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Months later, LogicBio exits FDA clinical hold for gene editing drug but won't restart trial until next quarter

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Soleno’s rare pediatric disease drug faces PDUFA delay by three months